Paris & Boston – (Business Wire) – Regulatory News:
Mauna Kea Technologies (Paris: MKEA) (OTCQX: MKEAY) (Euronext: MKEA) (” society “), The inventor of Cellvizio®, an interdisciplinary platform for probe and needle confocal laser endoscopy (p / nCLE), has prepared a preparatory document for the Joint General Assembly on June 2, 2022. We are announcing that it is available today at 2:00 pm at our registered office.
Meeting notices, including minutes, draft resolutions, and procedures for attending and voting at the meeting, were published on April 25, 2022, in Bulletin des Annonces Légales Obligatoires (BALO), Bulletin No. ° 49. Advertisement 2201108.
Notices of this meeting, as well as documents or information related to the Joint General Assembly and a single voting form, can be accessed from our website in the General Assembly’s dedicated space in the Investors section at the following address: https: //www.maunakeatech.com/en/investors/assemblee-generale.
Shareholders shall, under the conditions set forth in Articles R.225-88 and R.225-89 of the French Commercial Code, make the above documents upon a brief written request to our Registration Office below. You can also get it. 9rue d’Enghien-75010 Paris. However, we encourage our shareholders to prioritize sending all requests electronically to the following address: [email protected]
Prior to the shareholders’ meeting, our shareholders may exercise their voting rights by following the steps below, as detailed in the meeting notice published today on our website.
– – Postal or proxy voting (By giving an agent to the chair of the meeting or a third party, or without the indication of the agent) VOTACCESS is available electronically and should be used as a priority. The VOTACCESS Secure Platform will open on Monday, May 16, 2022 at 9 am (Paris time) and close on Wednesday, May 1, 2022.er June 2022 3:00 pm (Paris time). However, we strongly recommend that shareholders do not wait until the last few days to enter their voting instructions.
– – Exercise voting rights by letter or mail ;
– Shareholders too I personally attend the meeting.
In addition, shareholders will write in writing via the email address [email protected] or [email protected] to justify their status as shareholders until midnight May 27, 2022, prior to the shareholders’ meeting. You can ask a question.
Given the epidemic health situation of Covid-19, the procedure for holding a general meeting and physical participation in that meeting may vary depending on health and / or legal requirements until the day of the general meeting. Therefore, shareholders are encouraged to regularly visit the General Assembly-specific section of our website (https://www.maunakeatech.com/fr/investors/assemblee-generale). Here, the above conditions are specified and updated. Updated as needed.
About MaunaKea Technologies
Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, a real-time in vivo cellular imaging platform. This technology provides unique in vivo cell visualization that enables physicians to monitor disease progression over time, assess the reactions that occur, classify uncertain areas, and guide surgical interventions. Offers. The Cellvizio platform is used by many countries and several specialists around the world to transform the way physicians diagnose and treat patients. For more information, please visit www.maunakeatech.com.
This press release contains forward-looking statements about Mauna Kea Technologies and its business. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, we cannot guarantee the achievement of the forecasts shown in these forward-looking statements. These forecasts are at risk, including those listed in the Mauna Kea Technologies documentation database registered by Autorité des marchés financiers (AMF) in June. Under amendments to the 2020 Universal Registration Document submitted to AMF on number D-21-0566 and September 17, 2021. Both are only for the evolution of our website (www.maunakeatech.com) and the economic conditions, financial markets, and markets in which Mauna Care Technologies resides. The forward-looking statements contained in this press release also expose risks that Mauna Kea Technologies does not know about or that Mauna Kea Technologies does not consider materiality at this time. The realization of all or part of these risks is largely the result of Mauna Kea Technologies’ actual results, financial condition, performance or performance being shown in these forward-looking statements, as well as financial condition, performance or performance. It can lead to different things. This press release and the information contained therein do not constitute an offer to sell or subscribe to shares in Mauna Kea Technologies, or solicit a purchase or subscription order in any country.
NewCap – Investor Relations
+33 (0) 1 44 71 94 94